New treatment for fatigue and cognitive symptoms in PBC
Umecrine Cognition is developing golexanolone for the treatment of central fatigue and cognitive symptoms in chronic inflammatory diseases, with a primary focus on PBC.
Industry pharma
Ownership 59%
Umecrine Cognition is developing golexanolone, a drug candidate that affects the GABA system in the central nervous system. The most advanced development is focused on patients with primary biliary cholangitis (PBC) who suffer from significant fatigue and cognitive symptoms – problems that currently lack effective treatment.
The company’s randomized phase 1b/2a study included a total of 99 patients in the phase 2a part. In October 2026, Umecrine Cognition announced that the study did not meet its primary endpoint. Golexanolone is also being evaluated for continued development in, among other things, Parkinson’s disease.
In brief:
- 99 patients included in the phase 2a part
- Over 30 clinics in Europe and Turkey
- Primary endpoint not met in the phase 1b/2a study, as announced in October 2026